ORG-26576
識別資訊 | |
---|---|
| |
CAS號 | 1026791-61-6 |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C11H12N2O2 |
摩爾質量 | 204.23 g·mol−1 |
3D模型(JSmol) | |
| |
|
ORG-26576是一種有機化合物,分子式C11H12N2O2,最初由RespireRx公司(原稱Cortex Pharmaceuticals公司)的科學家研發,後交由歐加農公司繼續開發,能有效增強AMPA受體功能,促進腦源性神經營養因子釋放[1][2][3]。
參考文獻
- ^ Jordan GR, McCulloch J, Shahid M, Hill DR, Henry B, Horsburgh K. Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography. Neuropharmacology. August 2005, 49 (2): 254–64. PMID 15993447. S2CID 24805124. doi:10.1016/j.neuropharm.2005.03.011.
- ^ Su XW, Li XY, Banasr M, Koo JW, Shahid M, Henry B, Duman RS. Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus. Psychopharmacology. October 2009, 206 (2): 215–22. PMID 19603152. S2CID 19408716. doi:10.1007/s00213-009-1598-0.
- ^ Hamlyn E, Brand L, Shahid M, Harvey BH. The ampakine, Org 26576, bolsters early spatial reference learning and retrieval in the Morris water maze: a subchronic, dose-ranging study in rats. Behavioural Pharmacology. October 2009, 20 (7): 662–7. PMID 19741506. S2CID 27814943. doi:10.1097/FBP.0b013e328331ba1b.